Internal medicine journal
-
Internal medicine journal · Nov 2015
Epidemiology and risk factors for chronic kidney disease in Chinese patients with biopsy-proven lupus nephritis.
Lupus nephritis (LN) is one of the most serious complications of systemic lupus erythematosus (SLE). It is the most common secondary glomerulonephritis leading to end-stage renal disease. ⋯ Hypertension, anti-histone antibody and tubular atrophy are independent risk factors for CKD in Chinese LN patients.
-
Antibiotic resistance is a growing and worrying problem associated with increased deaths and suffering for people. Overall, there are only two factors that drive antimicrobial resistance, and both can be controlled. These factors are the volumes of antimicrobials used and the spread of resistant micro-organisms and/or the genes encoding for resistance. ⋯ We need to restrict the use of 'critically important' antibiotics in food animals and the entry of these drugs into the environment. We need to ensure that 'One Health' concept is not just a buzz word but implemented. We need to look at all sectors and control not only antibiotic use but also the spread and development of antibiotic resistant bacteria - both locally and internationally.
-
Internal medicine journal · Nov 2015
Creatinine as predictor value of mortality and acute kidney injury in rhabdomyolysis.
Rhabdomyolysis (RB) is a syndrome characterised by decomposition of skeletal muscle that could be life threatening, so the identification of biomarkers of its severity could help us in its treatment. Creatine kinase (CK) is usually taken as a reference in patients with RB in order to stratify prognosis, however that is not probably the most effective parameter. ⋯ Despite being a diagnostic marker for RB, initial CK levels do not predict mortality. However, creatinine initial levels are related to progression to acute renal injury and mortality at 30 days.
-
Internal medicine journal · Oct 2015
Multicenter StudyIpilimumab-induced hypophysitis in melanoma patients: an Australian case series.
Ipilimumab (Yervoy; Bristol-Myers Squibb) is a novel fully humanised monoclonal antibody that blocks cytotoxic T-lymphocyte antigen 4, an immune checkpoint molecule, to augment anti-tumour T-cell responses. It is associated with significant immune-related side-effects including hypophysitis. ⋯ There is significant morbidity associated with development of IH. We suggest guidelines to assist with early recognition and therapeutic intervention.